Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers August 14, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - August 14, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/14/18 - $150+ Bn Computer-Aided Drug Discovery Services Market, 2018-2030 [Sudan Tribune]
-The "Computer-Aided Drug Discovery Services Market, 2018-2030" report has been added to `s offering. The early stages of research related to drug discovery, including the identification of a relevant biological target and a viable lead compound, play a crucial role in the overall success of a drug candidate in preclinical an
8/14/18 - 'OTC Pharmaceutical Market Set to Grow to $183bn by 2022' Says Visiongain Report
Visiongain, a independent media company, issued the following news release:. Visiongain has launched a new pharma report Anti- Global OTC Pharmaceutical Market Forecast 2017-2027: Cough, Cold and Allergy, Analgesics, Gastrointestinal, Dermatology, Eye Care, Smoking Cessation Aids, Others. Leading companies featured in the report include Bayer AG,..
8/14/18 - (Ph No.:31134) Dvt Prophylaxis Stockings (Medium) above Knee Superior Quality Fda Approved
Address: Room No.312, IIIrd Floor, Railnilayam, Secunderabad-500071, Andhra Pradesh, Attn: Chief Administrative Officer. Description: Tenders are invited for Dvt Prophylaxis Stockings above Knee Superior Quality Fda Approved. Description: Dvt Prophylaxis Stockings above Knee Superior Quality Fda Approved Tender Closing Date Time: 17/08/2018 10:30.
8/14/18 - Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a business update and announced its operating and financial results for the first quarter ending June 30, 2018. Jan D Alvise, p
8/14/18 - AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY- AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common...
8/14/18 - Acorda Announces Management Transitions
Acorda Therapeutics, Inc. today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda s Chief of Business Operations, will assume responsibility for the company s Chelsea, MA manufacturi
8/14/18 - Actavalon Announces Appointments of Dr. John Hood to Its Board of Directors
"We believe the knowledge, insight and years of industry experience that Dr. Hood will bring to our board will be invaluable in successfully guiding the company over the next several years," said Krisztina Zsebo Ph.D., CEO of Actavalon. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed, a pharmaceutical c
8/14/18 - ActiGraph Announces New Scientific Affairs and Data Management Division
Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative in 2017, ActiGraph's Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the...
8/14/18 - Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
Actinium Pharmaceuticals, Inc., today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Trial of Iomab-B. Date: Wednesday, August 15, 2018 Time: 9:00 AM ET Registration Link: Toll-Free Dial-
8/14/18 - Action begins toward lowering drug prices [All Iraq News Agency (AIN)]
But experts who pay close attention to federal drug policy and Medicare rules say the administration is preparing to incrementally roll out a multipronged plan that tasks the Centers for Medicare& Medicaid Services and the Food and Drug Administration with promoting competition, attacking the complicated drug rebate system and introducing tactics t
8/14/18 - Adherium Launches Hailie Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management [Sport360]
-Adherium, a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie solution in the U.S., following its recent Food and Drug Administration 510 over-the-counter clearance to enable sales direct to consumers. Adherium believes health technology should be simple to use
8/14/18 - Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder, to confirm response to AEVI-001 in these patients. "We are pleased that we hav
8/14/18 - AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund []
-AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, announced today that it has entered into a common stock purchase agreement and registration rights..
8/14/18 - Albireo to Present at Wedbush PacGrow Healthcare Conference
BOSTON- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow Healthcare Conference at the Parker New York in New York City on Tuesday, August 14, 2018, at 8:35 a.m. ED
8/14/18 - Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
NEWTON- Allena Pharmaceuticals, Inc., a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena's President and Chief Operating Officer, will present a company...
8/14/18 - Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced the appointment of Susie Jun, M.D., Ph.D., as Chief Development Officer. Dr. Jun has also served as Senior Director, Hem/Onc Clinical Research, at Gilead, and as Executive Medical Director, Hematol
8/14/18 - Alnylams Onpattro is first ever FDA-approved RNAi drug [Arab Times (Kuwait)]
This is a significant victory for Alnylam, and for biotech in general, which has been struggling for more than a decade to transform RNAi technology into an approval medicine. Alnylam has beaten off competition in the US from RNAi company Ionis, which is developing a rival therapy for hATTR, Tegsedi. But Alnylam is ahead in the bigger US market, wh
8/14/18 - Amicus Galafold wins US approval [Sudan Tribune]
Amicus Therapeutics Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease. Galafold was approved using the Accelerated Approval pathway, which allows the US Food and Drug Administration to approve drugs for serious conditions where there is an unmet medical need if a treatment drug is shown
8/14/18 - Amicus oral Fabry disease drug approved in US [Arab News (Saudi Arabia)]
Amicus Therapeutics first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy. The oral drug is an alternative to the infused enzyme replacement therapy that is current standard of care Sanofi/ Genzymes Fabarazyme. Already approved in Europe,
8/14/18 - Amid pricing spat with U.K. government, Vertex won`t ask NICE to approve its new CF drug [Syrian Arab News Agency]
The battle between Vertex Pharmaceuticals and U.K. health officials over cystic fibrosis drug pricing has reached an impasse after NHS Englands final offer in July. In a statement, Vertex director of external communications Heather Nichols said the company supports the need for robust and fair medicines appraisal in England. Vertex and U.K. health.
8/14/18 - Amneal Pharmaceuticals Inc (NYSE:AMRX) price target raised to $21.00 by Canaccord Genuity
Analyst Ratings For Amneal Pharmaceuticals Inc (NYSE:AMRX) Today, Canaccord Genuity raised its price target on Amneal Pharmaceuticals Inc (NYSE:AMRX) to $21.00 per share. There are 4 Hold Ratings, 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Amneal Pharmaceuticals Inc (NYSE:AMRX) is Buy with a
8/14/18 - AMPIO PHARMACEUTICALS, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. This discussion should be read in conjunction with our historical financial statements. For additional information regarding these risks and uncertainties, please see Part II, Item 1 A of this Form 10- Q, "Risk Factors," and the risk factors included in our Annua
8/14/18 - Arbutus LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis [Sport360]
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that the Company`s lipid nanoparticle licensee, Alnylam Pharmaceuticals, Inc., announced that their new drug application for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration for the treatment o
8/14/18 - Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok
-Arch Biopartners, Inc., a portfolio-based biotechnology company, today announced it has engaged Dalton Pharma Services to perform the good manufacturing practice campaign for Metablok,, the Company's drug candidate for preventing acute kidney injury. said Peter Pekos, CEO and President, Dalton Pharma Services. " We are on schedule for producing a
Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading "Forward Looking Statements" and "Item 1 A. Risk Factors" under Part I of this Annual Report on Form 10- K, and in other reports we file with the SEC. Ther
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement